FibroGen Inc
FGEN
查看详细走势图
9.710USD
0.0000.00%
收盘 02/06, 16:00（美东）报价延迟15分钟
39.28M总市值
0.18市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
0.00%
5天
0.00%
1月
0.00%
6月
+11.48%
今年开始到现在
+10.59%
1年
-22.84%
查看详细走势图
TradingKey FibroGen Inc股票评分
单位: USD 更新时间: 2026-01-07操作建议
FibroGen Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名103/398位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价43.00。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
FibroGen Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
FibroGen Inc亮点
亮点风险
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
业绩增长期
公司处于发展阶段，最新年度总收入29.62M美元
估值高估
公司最新PE估值0.18，处于3年历史高位
机构减仓
最新机构持股1.14M股，环比减少33.14%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值184.24K
分析师目标
根据
2
位分析师
买入
评级
43.000
目标均价
+423.11%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
FibroGen Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
FibroGen Inc简介
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
公司代码FGEN
公司FibroGen Inc
CEOWettig (Thane)
网址https://www.fibrogen.com/
相关品种
